Maxim Group set a $1.00 price target on BioLineRx Ltd. (NASDAQ:BLRX) in a research note released on Tuesday morning. The firm currently has a hold rating on the stock.
Several other brokerages have also issued reports on BLRX. Roth Capital restated a buy rating and set a $7.00 price target on shares of BioLineRx in a research note on Monday, September 26th. Zacks Investment Research lowered shares of BioLineRx from a buy rating to a hold rating in a research note on Tuesday, October 11th. Finally, S&P Equity Research decreased their price target on shares of BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. BioLineRx presently has an average rating of Hold and an average price target of $2.68.
BioLineRx (NASDAQ:BLRX) opened at 1.05 on Tuesday. BioLineRx has a one year low of $0.71 and a one year high of $1.63. The stock’s 50 day moving average is $0.00 and its 200 day moving average is $0.00.
BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.01. On average, equities research analysts expect that BioLineRx will post ($0.28) EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. KCG Holdings Inc. increased its position in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares during the last quarter. Morgan Stanley increased its position in shares of BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock valued at $634,000 after buying an additional 66,900 shares during the last quarter. Finally, Senvest Management LLC increased its position in shares of BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock valued at $5,110,000 after buying an additional 900,200 shares during the last quarter. Institutional investors and hedge funds own 14.35% of the company’s stock.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioLineRx Ltd. and related companies with MarketBeat.com’s FREE daily email newsletter.